EA201992630A1 - Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf - Google Patents
Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegfInfo
- Publication number
- EA201992630A1 EA201992630A1 EA201992630A EA201992630A EA201992630A1 EA 201992630 A1 EA201992630 A1 EA 201992630A1 EA 201992630 A EA201992630 A EA 201992630A EA 201992630 A EA201992630 A EA 201992630A EA 201992630 A1 EA201992630 A1 EA 201992630A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- eye diseases
- aplnr
- vegf inhibitors
- treating eye
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 108091008803 APLNR Proteins 0.000 title abstract 2
- 102000016555 Apelin receptors Human genes 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 239000002525 vasculotropin inhibitor Substances 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 229960002833 aflibercept Drugs 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502621P | 2017-05-06 | 2017-05-06 | |
| PCT/US2018/031255 WO2018208625A1 (en) | 2017-05-06 | 2018-05-04 | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992630A1 true EA201992630A1 (ru) | 2020-04-29 |
Family
ID=62555166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992630A EA201992630A1 (ru) | 2017-05-06 | 2018-05-04 | Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3618876A1 (ko) |
| JP (1) | JP7161494B2 (ko) |
| KR (1) | KR102667021B1 (ko) |
| CN (1) | CN110709104A (ko) |
| AU (1) | AU2018266324B2 (ko) |
| CA (1) | CA3062418A1 (ko) |
| EA (1) | EA201992630A1 (ko) |
| IL (1) | IL270267B2 (ko) |
| MX (1) | MX2019012985A (ko) |
| WO (1) | WO2018208625A1 (ko) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| EP1613348B1 (en) | 2003-03-12 | 2010-06-23 | The Arizona Board of Regents on Behalf of the University of Arizona | Methods for modulating angiogenesis with apelin compositions |
| AU2006214658A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| EP3753548A1 (en) | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US8946382B2 (en) | 2009-02-27 | 2015-02-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Apelin peptides and methods of use |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2734546A1 (en) | 2011-07-18 | 2014-05-28 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
| AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| US9593153B2 (en) | 2012-04-11 | 2017-03-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Modified apelin polypeptides |
| JP5775851B2 (ja) | 2012-06-27 | 2015-09-09 | 東京エレクトロン株式会社 | 塗布装置および塗布液充填方法 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2970415B1 (en) * | 2013-03-14 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| JP6483117B2 (ja) * | 2013-11-20 | 2019-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ａｐｌｎｒモジュレーター及びその使用 |
| CA2942940A1 (en) | 2014-03-20 | 2015-09-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| TWI748962B (zh) * | 2015-09-23 | 2021-12-11 | 美商建南德克公司 | 抗ｖｅｇｆ抗體之最佳化變異體 |
-
2018
- 2018-05-04 CA CA3062418A patent/CA3062418A1/en active Pending
- 2018-05-04 AU AU2018266324A patent/AU2018266324B2/en active Active
- 2018-05-04 CN CN201880037918.XA patent/CN110709104A/zh active Pending
- 2018-05-04 IL IL270267A patent/IL270267B2/en unknown
- 2018-05-04 JP JP2019560665A patent/JP7161494B2/ja active Active
- 2018-05-04 EA EA201992630A patent/EA201992630A1/ru unknown
- 2018-05-04 MX MX2019012985A patent/MX2019012985A/es unknown
- 2018-05-04 WO PCT/US2018/031255 patent/WO2018208625A1/en active Application Filing
- 2018-05-04 KR KR1020197035953A patent/KR102667021B1/ko active IP Right Grant
- 2018-05-04 EP EP18729829.4A patent/EP3618876A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL270267A (ko) | 2019-12-31 |
| AU2018266324B2 (en) | 2024-02-01 |
| CA3062418A1 (en) | 2018-11-15 |
| IL270267B1 (en) | 2024-02-01 |
| KR20200004366A (ko) | 2020-01-13 |
| WO2018208625A1 (en) | 2018-11-15 |
| MX2019012985A (es) | 2020-01-13 |
| KR102667021B1 (ko) | 2024-05-21 |
| JP7161494B2 (ja) | 2022-10-26 |
| CN110709104A (zh) | 2020-01-17 |
| JP2020518641A (ja) | 2020-06-25 |
| AU2018266324A1 (en) | 2019-11-28 |
| IL270267B2 (en) | 2024-06-01 |
| EP3618876A1 (en) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| EA201792047A1 (ru) | Новые соединения | |
| EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
| EA201500364A1 (ru) | Лечение глазных заболеваний | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| MX2019001021A (es) | Formulaciones de liposomas. | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201991511A1 (ru) | Кристаллическая структура гремлин-1 и ингибирующее антитело | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| EA201891342A1 (ru) | Изоиндольные соединения | |
| EA202091221A1 (ru) | Способ лечения или предотвращения идиопатической полипоидной хориоидальной васкулопатии (ипхв) | |
| CY1121933T1 (el) | Υποκατεστημενες δικυκλικες διυδροπυριμιδινονες και χρηση αυτων ως αναστολεις δραστικοτητας ελαστασης ουδετεροφιλου | |
| EA202190094A1 (ru) | Антитела против cd40 для применения в лечении аутоиммунного заболевания | |
| EA201790590A1 (ru) | Гуманизированное моноклональное антитело, ингибирующее ферментативную активность сосудисто-эндотелиальной липазы | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
| EA202192400A1 (ru) | Антитела против интегрина и их применение |